Genasense AC review
Executive Summary
Genta's chronic lymphocytic leukemia treatment Genasense will be reviewed by FDA's Oncologic Drugs Advisory Committee Sept. 6, the company said. The oblimersen injection plus chemotherapy regimen is currently pending at FDA under a standard review, with an Oct. 29 user fee date. Genta initially sought a melanoma indication, but withdrew the NDA in May 2004 following a negative advisory committee review (1"The Pink Sheet" May 24, 2004, p. 12)...